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CC BY-NC-ND license (http://creativeAbstract Background: Chronic heart failure (CHF) is characterized by insufficient blood sup-
ply from heart to meet the body’s metabolic demands. Integrating Western and traditional Chi-
nese medicine to treat CHF has proved a validated therapeutic approach. In recent years,
metabolomics has been regarded as a potential platform to provide biomarkers for disease-
subtypes.
Objective: To examine 38 patients, combined NMR plasma metabolomics and traditional Chi-
nese medicine diagnosis in order to identify diagnostic biomarkers for two CHF syndrome sub-
types.
Methods: After processing the spectra, orthogonal partial least square discriminant analysis
was performed, and the contributing NMR signals were analyzed using Y-scrambling statistical
validation with good reliability.
Results: Plasma metabolic patterns of yin deficiency and yang deficiency patients were clearly
discriminated. The yin-deficiency group had increased level of lactate, glycoprotein, lipopro-
tein and lower levels of glucose, valine and proline. The yang-deficiency group had higher
levels of lactate, glycoprotein and pyruvic acid, and lower levels of glucose and lipoprotein.10 64286506; fax: þ86 010 64286271.
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Subtypes of chronic heart failure 81Potential biomarkers of CHF based on the two traditional Chinese medicine syndromes indi-
cated alternative modes of metabolites and metabolic pathways in the disease, e.g. dysfunc-
tion of energy utilization and disturbance in fatty acids, amino acids.
Conclusion: This study suggests that combining metabolomics with traditional Chinese medi-
cine diagnosis can reveal metabolic signatures for CHF syndrome subtypes. The plasma metab-
olites identified might be of special clinical relevance for subtypes of CHF, which could lead to
further understanding of mechanisms involved and an improvement in personalized treatment
for CHF.
ª 2015 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Chronic heart failure (CHF), a progressive clinical syndrome
characterized by the inability of the heart to adequately
pump blood to meet metabolic demands of the body. It
represents the final common pathogenesis in various causes
of heart damage.1 Despite a substantial improvement in the
survival rate after the onset of CHF because of increasing
use of pharmacological interventions, the mortality of pa-
tients suffering from CHF remains high. It is well recognized
that the incidence and prevalence of CHF is expected to
increase further with the aging population, better strate-
gies for the prevention and treatment of CHF is required.
With progress in bioinformatics and medical science, the
focus on health and disease in Western life sciences has
shifted from standard protocol-based disease management
to personalized medicine. Based on personalized health
and systematical diagnostic principles, traditional Chinese
medicine (TCM) has proved clinically effective at restoring
the self-regulatory ability of the human system for thou-
sands of years. Using integrated TCM and Western medicine
to treat CHF has been reported to enhance heart function
and reduce related clinical symptoms, including expiratory
dyspnea and chronic fatigue, and subsequently improve
echocardiographic measures, the 6-min walking distance
test and patients’ quality of life.2 TCM physicians also pay
increased attention to overall maladjustments of the
functional status called ‘syndrome type’.3 It is not simply
an assemblage of the signs and symptoms of diseases, but
also a functional status caused by the reaction to, or
interaction with, environmental changes and pathogenic
factors.4 The essence of TCM ‘syndrome type’ is the
disturbance in biological metabolism networks, and
changes in concentration and relative proportions of
metabolomics biomarkers resulting from an imbalance in
the human system.
Metabolomics, an important component of systematical
biology, can be used to perform dynamic studies on non-
injured tissues and organs in vivo and in vitro using non-
invasive approaches under nearly physiological conditions.5
Therefore, metabolomics detection and analysis of biolog-
ical samples may contribute to understand the biochemical
changes associated with the progression of diseases. And
identification of disease-associated metabolic biomarkers
could allow early diagnosis of disease and establishment of
predictive diagnostic systems. It is reported that metab-
olomics gives unparalleled advantage to the most commoncardiovascular condition encountered in clinical practice,
heart failure.6 Metabolomics has also shown significant
potential in TCM studies in recent years. And several
studies7,8 combining metabolomics techniques and TCM
syndrome types have demonstrated fingerprints of meta-
bolic changes that characterize Western medicine diag-
nosed diseases, which highlight the potential of
metabolomics in the evaluation of disease condition and
TCM-guided personalized treatment.
As one of the most used metabolomics analysis plat-
forms, nuclear magnetic resonance (NMR) spectroscopy has
been widely applied to metabolomics research as it pro-
vides the advantages of high resolution and high sensitivity.
Thus, NMR is useful for revealing systematically the
metabolomics pathways and mechanisms involved in CHF
through exploring TCM syndromes and therapies.
The current research was a parallel comparative study
that analyzed plasma metabolites of 38 CHF patients using
NMR spectroscopy to examine:
(1) potential metabolic biomarkers contributing to
discriminate TCM syndrome types (yang-deficiency
vs. non-yang-deficiency, and yin-deficiency vs. non-
yin-deficiency); and
(2) similarities and differences in TCM syndrome-related
biomarker patterns. We hypothesize that combining
TCM diagnosis with metabolomics could provide
quantitative biological evidence for TCM diagnosis by
identifying CHF subtypes with related plasma meta-
bolic patterns.Materials and methods
Participants and study design
The study was designed as an explorative study without
intervention. Patients with a history of coronary heart
disease that met the CHF diagnostic criteria in accordance
with the Guidelines for the Diagnosis and Management of
Chronic Heart Failure established by the Chinese Society of
Cardiology of the Chinese Medical Association in 2007 were
enrolled. Eligibility criteria were age 45years and left
ventricular ejection fraction <50%. All patients were in
New York Heart Association (NYHA) classes IIeIV. All pa-
tients underwent our standardized recruitment and
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doctors independently to reduce subjective factors. A pre-
study screening involved a physical exam that included
echocardiography and clinical laboratory tests and was
performed immediately. Patients with end-stage renal or
liver disease, ongoing infection and long-term immuno-
suppressive therapy were excluded.
Thirty-eight patients attending the Heart Diseases Clinic
at Beijing University of Chinese Medicine Affiliated Hospital
from January 2013 to September 2014 were finally enrolled
in the study. Samples of venous blood were collected, and
the detailed clinical data are shown in Table 1.
The study was approved by the Ethical Committee at the
Affiliated Hospital of Beijing University of Chinese Medi-
cine, and written informed consent was acquired from all
participants recruited.
We used TCM to, investigate general syndromes and
classified them into two study groups: (1) yin-deficiency
vs. non-yin-deficiency (Group 1); and (2) yang-deficiency
VS non-yang-deficiency (Group 2). According to Clinical
Terminology of Traditional Chinese Medical Diagnosis and
TreatmentdSyndromes,9 yin-deficiency is described as
low fever, night sweats, afternoon zygomaticus red,
dysphoria with feverish sensation of the chest palms and
soles, dry mouth and throat, red tongue with little coating
and thready rapid pulse. And yang-deficiency is a cluster
of symptoms including an aversion to cold, dispirited
feelings and lack of motivation, diarrhea before dawn,
shortness of breath, frequent urination, edema, and lia-
bility to catch cold. Using these criteria, 15 patients were
assessed as being in the yin-deficiency group and 7 pa-
tients as being in the yang-deficiency group, others of 38
patients were diagnosed as being in combined syndromes
of CHF.Table 1 Demographic details of participants.
Patients (n Z 38) Mean  SD Range
Age/years 61.4  5.13 45e79
BMI/kg m2 28.8  2.4 25.6e35.5
Sex M:F 21/17 e
Median NYHA class 3 e
Mean ejection fraction 54.3  8.2 41e67
Etiology ischemic:
non-ischemic
22/16 e
Hypertensive: non-
hypertensive
20/18 e
Hyperlipidemia: non-
hyperlipidemia
14/24 e
DM: non DM 15/23 e
Smoker: non-smoker 17/21 e
Naþ 142.6  4.3 127e147
Kþ 3.9  0.6 0.9e4.8
Urea 7.1  2.1 3e14
Creatinine 101  32 43e229
Hemoglobin 128.7  20.1 79e175
Beta-blokers Y:N 20/18 e
ACE inhibitors Y:N 14/24 e
Diuretics Y:N 19/19 eSample collection and preparation
Clinical parameters included gender, age, ejection frac-
tion, creatinine, electrolyte, urea, B-type natriuretic pep-
tide, platelet count, hemoglobin, fasting blood glucose,
triglyceride levels and total cholesterol. Complications
including diabetes, hypertension or dyslipidemia, and drug-
taking information of patients were noted at inclusion.
Venous blood of 38 CHF patients at the Heart Failure
Clinic were also collected in 5 mL Vacutainer tubes with
chelating agent ethylene diamine tetraacetic acid (EDTA)
and centrifuged at 3000 rpm for 10 min. The blood sample
was then separated into equal aliquotsand stored at 80C
until analysis.10
For NMR analysis, plasma samples were thawed at room
temperature. After being centrifuged at 13 000 rpm for
10 min, 200 mL samples of supernatant were removed. D2O
(400 mL) was added and the mixture was centrifuged again.
Following centrifugation, 550 mL of supernatant was trans-
ferred to a 5-mm diameter specific NMR tube for NMR
analysis. The reaction was performed using a Varian VNMRS
600 MHz NMR spectrometer (Varian Medical Systems, Inc.,
Palo Alto, CA, USA) at 25C.
1H-NMR spectroscopy
The spectra were acquired by CarrPurcellMeiboomGill
(CPMG) sequence D-[90-(t-180-t)n-ACQ] and Longitudi-
nal Eddy-Delay (LED) sequence. Both small molecular me-
tabolites and lipid components in the plasma were observed
respectively. The free induction decays were transferred
into 64 K data points with a spectral width of 8000 Hz and
64 scans, then zero-filled to double size and multiplied
before Fourier transformation, which was applied with an
exponential window function to produce a 0.5 Hz broad-
ening line. We identified plasma metabolites by comparison
with chemical shifts, which is detailed in a previous
report.11
Spectral and statistical analysis
Spectra were manually phased, baseline corrected and
normalized. Each spectrum was referenced using internal
lactate CH3 resonance at d1.33 by Mest-ReNova7.1.0 soft-
ware (Mestrelab Research, A Corun˜a, Spain). Signals from
d0.5 to d9.0 for each sample were automatically binned
with a 0.005 ppm width. Water and EDTA metal complex
regions were excluded.12
Prior to multivariate data analysis, statistical analyzes
were performed on the data using SIMCA-Pþ12 software
(Umetrics, Umea, Sweden) as variables and then mean-
centered and pareto-scaled.
To analyze the NMR data holistically and discriminate
CHF patients with different TCM syndrome types and con-
trols, we applied both principal component analysis and
orthogonal partial least-squares discriminant analysis
(OPLS-DA).13,14
Score and loading plots were calculated to demonstrate
discriminatory metabolites for each group. Each point in a
score plot pointed to the projection of a NMR spectrum
(patient sample) on the predictive (horizontal axis) and
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loading plot, positive signals represented those plasma
metabolites revealed increased concentrations in CHF pa-
tients diagnosed with yin-deficiency or yang-deficiency
syndrome. Accordingly, a negative signal corresponded to
those down-regulated plasma metabolites.15
The key metabolites resulting in discrimination were
also analyzed by peak integration. And independent sam-
ples t-test were used to identify main differences in
selected signals.
To obtain a more objective statistical estimation, we
performed ‘Y-scrambling’ validation and calculated R2
(correlation coefficients) and Q2 (prediction properties)
values to evaluate our OPLS-DA models.16
Results
Clinical characteristics of participants
Detailed clinical data characteristics and plasma samples
acquired from all CHF patients with different TCM syn-
drome types were collected. The groups showed no dif-
ferences in any demographic characteristic, such as gender,
age or body mass index.
Metabolomics analysis of plasma samples of CHF
with TCM syndromes
As metabolomics has the advantage of being able to iden-
tify metabolomics biomarker profiles and reveal relation-
ships among TCM syndrome subtypes, metabolic profiling
coupled with multivariate analysis was applied in this study.Fig. 1 OPLS-DA score plots of Group 1. Black box: OPLS-DA scor
patients. Red circle: OPLS-DA score plots displaying discriminationBased on metabolic profiling, CHF patients with yin-
deficiency or yang-deficiency and controls were able to be
easily distinguished in principal component analysis score
plots. The first two principal components were selected,
which described 65.7% of the total variance of the plasma
metabolome.
OPLS-DA is a newly developed data analysis method
combining orthogonal signal correction and partial least
squares, and has been widely used in clinical studies.10,17
Here, we also performed an OPLS-DA pattern recognition
model with one predictive component and four orthogonal
components to further identify plasma metabolites that
differed in concentrations in CHF patients with different
TCM syndrome types. OPLS-DA score plots revealed that
yin-deficiency patients were statistically distinguishable
from controls (R2Y Z 0.608 Q2 Z 0.327). The former index
shows the explanative ability of the syndrome classifica-
tion, and the latter is the result of seven-fold cross-vali-
dation, and suggests that the OPLS-DA models were
robust.18 The patterns of Group 1 and 2 are clearly distinct
from that of the control group along the t[1]-axis direction
of the first principle component, without any crossover or
overlap (Figs. 1 and 2). This separating trend clearly in-
dicates that metabolic profiling varied according to
different TCM syndromes.
Further analysis of loading plots illustrated correspond-
ing changes of metabolites of high variable importance,
which accounted for metabolomics fingerprint changes and
discrimination in score plots. Nine plasma metabolites of
yin-deficiency patients and control groups could be deter-
mined in the 600 MHz one-dimensional CPMG and LED1 H-
NMR spectra, ranked by the largest variable importance,19
to be significantly altered metabolites of CHF patientse plots displaying discrimination between CHF yang-deficiency
between CHF yang-deficiency controls.
Fig. 2 OPLS-DA score plots of Group 2. Black box: OPLS-DA score plots displaying discrimination between CHF yang-deficiency
patients. Red circle: OPLS-DA score plots displaying discrimination between CHF yang-deficiency controls.
84 J. Wang et al.with yin-deficiency syndrome (i.e. potential biomarkers)
(Figs. 3, 4 and Table 2A). CHF patients with yang-deficiency
syndrome were examined as above. Nine metabolites were
positively identified as potential biomarkers from variable
importance values (Figs. 5, 6 and Table 2B).Fig. 3 OPLS-DA loadings plots of key metabolites by CPMG s
discrimination of key metabolite levels between CHF yin-deficiencStatistical validation
We performed ‘Y-scrambling’ statistical validation to cor-
rect chance correlation and evaluate the OPLS-DA model.
The Y-variable of case and control group were randomlyequence of Group 1. OPLS-DA loadings plots demonstrating
y patients and controls.
Fig. 4 OPLS-DA loadings plots of key metabolites by LED sequence of Group 1. OPLS-DA loadings plots demonstrating discrimi-
nation of key metabolite levels between CHF yin-deficiency patients and controls.
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addition, we recorded and analyzed trends of the predic-
tive power and goodness of fit at each step. Two hundred
rounds of reshuffling showed that the separation model was
reliable, and that its high predictability was not affected by
random or over-fitting of the data, as both permutated R2
and Q2 values were markedly lower than the corresponding
original values (Fig. 7A, B). Even though this study may not
include all possible confounding factors in the patients, our
validation through randomization of the Y-variable suggests
that these variations should not be key attributors for
discrimination between case and control groups, or affect
the predictability of our model.Table 2A Key metabolites differentiating CHF yin-deficiency pa
No Metabolite (Chemical shift) YI
1 Valine 1.04 0.
2 VLDL/LDL 1.26, 1.3, 1.34 1.
3 Lactate 1.33, 4.12 1.
4 Alanine 1.48 0.
5 Proline 3.33 0.
6 Glucose 3.47; 3.72, 4.64, 5.23 4.
7 Glycoprotein (NeAc) 2.02 0.
8 Carnitine 2.44 0.
Abbreviations: YIP, yin-deficiency patients; NYIP, non-yin deficiency p
poprotein; HDL, high-density lipoprotein; Values expressed as the me
samples T Test; Variable importance in the projection (VIP) was acquDiscussion
CHF is clinically associated with high mortality and
morbidity, decreased quality of life and substantial burden
on health care systems. Despite advances in drug treatment
strategies for CHF, the number of deaths resulting from this
condition continues to rise.20 TCM pays particular attention
to the integrity and holism of the human body and its inter-
relationship with nature. TCM also adheres to basic princi-
ple of treatment based on differentiation of symptoms and
signs, treats the same disease by different methods and
different diseases by the same method, and advocates
individualized treatment, which vividly reflects the essencetients and controls.
P NYIP P-value VIP
2526  0.0628 0.3031  0.0507 0.007 1.76
6539  0.0885 1.5791  0.0996 0.010 2.59
4396  0.4708 1.1235  0.2363 0.017 3.99
2748  0.0873 0.4077  0.1251 0.000 2.11
0353  0.0283 0.0511  0.0226 0.029 3.93
1008  0.4777 4.7331  0.6542 0.007 3.68
6093  0.0223 0.4289  0.0696 0.000 2.54
0725  0.0138 0.0904  0.0351 0.001 2.39
atients; LDL, low-density lipoprotein; VLDL, very low-density li-
an(SD) (range); P values were calculated from the Independent-
ired from the OPLS-DA model.
Fig. 5 OPLS-DA loadings plots of key metabolites by CPMG sequence of Group 2. OPLS-DA loadings plots demonstrating
discrimination of key metabolite levels between CHF yin-deficiency patients and controls.
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entiation is at the core of TCM therapy for CHF.
In terms of the perspective of TCM, CHF may occur in all
differentiation types, including yang deficiency, blood sta-
sis and yin-deficiency, to name a few. Some Chinese herbs
have been demonstrated to be safe and effective in theFig. 6 OPLS-DA loadings plots of key metabolites by LED sequen
nation of key metabolite levels between CHF yin-deficiency patienmanagement of CHF in both animal models and in
humans.22,23 Modern biological research has now begun
integrating various research technologies and methods to
tackle difficult biological problems at bio-molecular levels,
which is exemplified by studies in the new scientific field of
metabolomics. It is important that potential correlationsce of Group 2. OPLS-DA loadings plots demonstrating discrimi-
ts and controls.
Table 2B Key metabolites differentiating CHF yang-deficiency patients and controls.
No Metabolite (Chemical shift) YADP NYADP P-Value VIP
1 HDL 0.82 0.1447  0.0439 0.1979  0.0468 0.0180 2.51
2 Pyruvic acid 0.94 0.0967  0.0181 0.0667  0.0106 0.000 1.45
3 VLDL/LDL 1.26, 1.3, 1.34 1.5539  0.0885 1.8791  0.0996 0.010 2.50
4 Lactate 1.33, 4.12 1.4396  0.4708 1.1235  0.2363 0.017 3.70
5 Alanine 1.48 0.4748  0.0873 0.2077  0.1251 0.000 2.03
6 Glutamate 2.15, 2.52 0.0829  0.0169 0.0586  0.0189 0.000 1.95
7 Glucose 3.47; 3.72, 4.64, 5.23 4.1008  0.4777 4.5371  0.6542 0.007 3.01
8 Glycoprotein (NeAc) 2.02 0.6093  0.0223 0.4289  0.0696 0.000 2.38
Abbreviations: YAP, yang-deficiency patients; NYAP, non-yang deficiency patients; LDL, low-density lipoprotein; VLDL, very low-density
lipoprotein; HDL, high-density lipoprotein. Values are expressed as mean (SD) (range). P-values were calculated from independent
samples t-tests. Variable importance in the projection (VIP) was acquired from the OPLS-DA model.
Subtypes of chronic heart failure 87between TCM syndrome type and metabolites are investi-
gated to develop novel therapeutic approaches for better
treatment of CHF.
In this explorative study, we investigated plasma metabo-
lites of CHF patients with yin-deficiency and yang-deficiency
syndrome to examine new approaches to diagnosis and iden-
tify metabolic signatures of TCM syndromes in CHF. Our
approachcombinedplasmametabolomicswithTCMsyndrome
type diagnosis showed performances for each study group.
With the aim of evaluating the diagnostic performance
of plasma metabolites in this study, we identified distin-
guishable metabolites able to differentiate CHF patients
with each TCM syndrome from controls, including energy
metabolites (glucose, lactate and glycoprotein), lipid/pro-
tein complexes (high-density lipoprotein (HDL), low-density
(LDL)/very low-density lipoprotein (VLDL)) and amino acids
(alanine, glutamate, valine, glycine, proline and carnitine).
From the results, it is suggested that this metabolomics
method shows potential to help in the understanding of
TCM syndromes of CHF.
As with all new diagnostic approaches, this study had
some limitations. First, there is the possibility of other
confounding factors having an effect on metabolic profiles.
Further, studies using larger cohorts are required to vali-
date this method. Second, as plasma samples are repre-
sentative of metabolic process in different organs, it is
difficult to assign a metabolic fingerprint to specific meta-
bolic processes.24 However, altered metabolite levels are
at least partly reflected in CHF patients with certain TCM
syndromes, which can be suggestive of markers of diseases.
Further mechanistic studies are required on this point.
In the current study, yin-deficiency patients showed a
distinct altered metabolism, including increased levels of
lactate, glycoprotein and LDL/VLDL, and lower levels of
glucose, valine, proline, alanine and carnitine compared
with non yin-deficiency patients.
Heart failure is characterized by alterations in energy
metabolism, and a high level of lactate and a decreased
level of glucose in the blood points to energy metabolism
dysfunction in CHF patients with yin-deficiency.18 Glyco-
protein is closely associated with the physiology and pa-
thology of cell growth and can affect human metabolic
energy supply and cellular immunity.25 We observed
increased levels of LDL and VLDL in CHF patients with yin-
deficiency, which were the most prominent factors differ-
entiating yin-deficiency patients from the control groups.This metabolomics profile could be associated with lipolysis
as a backup mechanism for energy utilization, because
apolipoproteins are important in lipid metabolism.
It has been reported that increased levels of proline play a
role in coronary atherosclerotic disease patients with yin-
deficiency syndrome.26 The plasma levels of well-known
essential and non-essential amino acids (such as alanine and
valine) were observed to be low in CHF patients with yin-
deficiency syndrome, which gradually breaks the internal
equilibrium of the body. This observation aligns with research
by Yan et al. (a metabolomics study using a rat model of
myocardial ischemia with both qi-deficiency and yin-
deficiency syndromes) that showed increased inositol and
decreased valine, glycine and serine were closely associated
with energy metabolism and oxidative stress response.27
Additionally, carnitine is an important substance involved in
fat metabolism and energy supply, and was seen to reduce
dramatically in these patients. Studies have confirmed that L-
carnitine can increase the uptake of free fatty acids, which
makes use of glucose as oxidative fuel in certain circum-
stances.28,29 If there is an insufficient supply of carnitine, the
oxidation process in mitochondria will be affected, which
leads to an imbalance in cellular metabolism and heart dis-
eases. The tricarboxylic acid cycle, carbohydrates, proteins
and fats are involved in the above metabolic processes, and
the indicative of a complicated metabolic disorder in CHF
patients with yin-deficiency syndrome.
Secondly, yang-deficiency patients showed higher levels
of lactate, glycoprotein, pyruvic acid, alanine and gluta-
mate, and lower levels of glucose, LDL/VLDL and HDL
compared with non-yang-deficiency patients. Based on TCM
theory, yang-deficiency is associated with signs of chronic
weakness, hypofunction, hypometabolism and degenera-
tive symptoms and is commonly observed in late or severe
stages of many diseases.30 The metabolism pattern in CHF
patients with yang-deficiency showed decreases in glucose
metabolism and increases in lactate, alanine and pyruvate,
suggesting that carbohydrate and energy metabolism dis-
orders in these patients was serious. There might be
enhanced endogenous glucose production from gluconeo-
genesis and pyruvic acid change may indicate increased
hepatic gluconeogenesis to provide extra pyruvate as a
substrate for glucose.31
Consistent with these findings, yang-deficiency syn-
drome typically occurs in patients with CHF at stage III and
stage IV. Additionally, increased glycoprotein levels
Fig. 7 (A) Statistical validation of the OPLS-DA model of Group 1. A permutation test performed with 200 random permutations in
a PLSDA model showing R2 (green triangles) and Q2 (blue boxes) values from permuted analysis (bottom left) as significantly lower
than corresponding original values (top right). (B) Statistical validation of the OPLS-DA model of Group 2. A permutation test
performed with 200 random permutations in a PLSDA model showing R2 (green triangles) and Q2 (blue boxes) values from permuted
analysis (bottom left) as significantly lower than corresponding original values (top right).
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lower lipoprotein levels, including LDL/VLDL and HDL,
suggest insufficient absorption and utilization of protein
during these phases. Higher excretion levels of measured
metabolites (glutamate and alanine) in Group 2 partici-
pants could indicate further more potential disturbances of
renal function, resulting in these patients missing metab-
olites necessary for carbohydrate and energy metabolism.33
A study in China investigated urinary metabolites of
yang-deficiency syndrome in patients with chronic kidney
disease and reported that key distinguishing metabolites
differing between yang-deficiency syndrome patients and
the control group included alanine, diethylamine and pro-
line.34 As essential substances in cellular activities, such
deficiencies will affect energy supply in all aspects of the
human body. These alterations are likely important
contributing factors to the altered metabolite profiling of
CHF patients with yang-deficiency syndrome.
This study is an early phase investigation examing TCM
syndrome types of CHF based on a small number of study
participants. Importantly, this study has demonstrated that
two TCM syndromes were able to be distinguished based on
their plasma metabolic patterns. While the findings of this
study are very promising, further research using larger
cohort is required to confirm and validate the reliability of
individualized treatment of CHF based on TCM subtypes.
Conclusion
The current study applied biology-based NMR plasma
metabolomics with TCM personalized diagnosis to find
metabolic subtypes in CHF. Two TCM syndrome subtypes of
CHF were identified by plasma metabolomics and showed
different metabolic patterns. Group 2 had lower levels of
sugars, proteins, fats and amino acids compared with Group
1, indicating increased disturbances in and carbohydrate and
energy metabolism and renal function in these patients. The
identified plasma metabolites may be of special clinical
relevance for the diagnosis of subtypes of CHF and for
uncovering metabolomics pathways and prognosis in some
cases, which could lead to a better understanding of, and
improvement in, personalized interventions for CHF. Future
studies are needed to validate the TCM subtypes identified in
this study, and to assess intervention responses of these TCM
subtypes to potential metabolic therapy or drugs.
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